Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass.
Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass.
复制标题
通过总骨矿物质量的变化评估大力补对绝经后骨消耗的影响。
DOI：
10.1016/0026-0495(77)90073-7
复制
发表时间：
1977
期刊：
影响因子：
--
通讯作者：
J. Denney
中科院分区：
文献类型：
--
作者：
C. Chesnut;W. Nelp;D. Baylink;J. Denney
为评价美雄龙治疗骨质疏松症的疗效，对13名绝经后骨质疏松症患者和13名对照(安慰剂)女性进行了26个月的双盲研究。药物效果主要是通过中子活化分析测定全身钙(TBC)来评估的，本质上是测量总骨矿物质质量。结果在完成研究的16名患者(10名接受治疗，6名服用安慰剂)以及所有26名参与研究的患者中，治疗组和对照组之间的TBC变化显示出显著差异(P<；0.01)。在退出的患者中，TBC在退出期间的变化与完成研究的患者相似。在那些完成研究的患者中，治疗组的TBC增加了2%，安慰剂组下降了3%。需要骨骼外钙平衡的大约6倍的差异来解释观察到的组间TBC差异的大小。在26个月的观察期内，药物效应似乎一直存在。因此，这些数据有力地表明，长期使用美雄龙治疗绝经后骨质疏松症预防了骨丢失；它增加骨量超过初始值的可能性不太确定。
To assess the efficacy of methandrostenolone in the treatment of osteoporosis a 26-mo double-blind study was performed with 13 treated and 13 control (placebo) postmenopausal osteoporotic females. Drug effect was assessed primarily by determinations of total body calcium (TBC) by neutron activation analysis, essentially a measurement of total bone mineral mass. Results in the 16 patients completing the study (10 treated and 6 placebo), as well as in all 26 patients participating in the study, showed significant (p< 0.01) differences in the change in TBC between treated and control groups. In patients dropping out, TBC changes through the time of dropout were similar to those in patients completing the study. In those patients completing the study, TBC increased 2% in the treated group and decreased 3% in the placebo group. An approximate sixfold difference in extraskeletal calcium balance would be required to explain the magnitude of the observed intergroup TBC difference. The drug effect appeared to persist throughout the 26-mo observation period. Thus these data strongly suggest that long-term use of methandrostenolone in postmenopausal osteoporosis prevented bone loss; the possibility that it increased bone mass above initial values is less certain.